Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo, dated December 10, 2002, reports on the announcement of clinical trial results for the drug Arixtra (fondaparinux sodium). The filing covers the MATISSE program results presented at the 44th annual meeting of the American Society of Hematology in Philadelphia on December 9, 2002.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a current report focused exclusively on clinical trial outcomes and regulatory developments rather than financial performance.
Material Changes and Clinical Findings
The primary material event is the successful completion of the MATISSE clinical trials, which evaluated Arixtra for the initial treatment of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT).
- MATISSE PE Trial: Involved 2,213 patients. Arixtra (7.5 mg once daily) showed a recurrent VTE rate of 3.8% compared to 5% for unfractionated heparin (UFH). Major bleeding rates were comparable (1.3% vs 1.1%).
- MATISSE DVT Trial: Involved 2,205 patients. Arixtra showed a recurrent VTE rate of 3.9% compared to 4.1% for enoxaparin (LMWH). Major bleeding rates were comparable (1.1% vs 1.2%).
- Conclusion: Arixtra demonstrated it is at least as effective and as safe as current standard therapies (UFH and LMWH) with the added benefit of a fixed once-daily subcutaneous dose, facilitating outpatient treatment.
Outlook, Management Commentary, and Risks
Regulatory and Commercial Outlook: Sanofi-Synthelabo plans to make regulatory submissions for new indications and dosage forms based on these results. Arixtra is already approved in the US and EU for VTE prophylaxis in major orthopedic surgery.
Future Developments: Investigations are ongoing for VTE prophylaxis in general surgery and medical patients. A major program in arterial thrombosis is planned.
Risks and Contingencies: The filing notes that while efficacy trends favored Arixtra in the PE trial, the relative risk reduction was not statistically significant in the intention-to-treat analysis. The drug is co-developed with Organon.
Key Facts for Investor Verification
- Verify the timeline for regulatory submissions to the FDA and EMA for the new treatment indications (PE and DVT).
- Confirm the commercial launch strategy for Arixtra in the treatment market versus the existing prophylaxis market.
- Monitor the progress of the planned arterial thrombosis program and ongoing general surgery trials.
- Review the co-development agreement terms with Organon regarding revenue sharing for new indications.